Holyoake T L, Nicolini F E, Eaves C J
British Columbia Cancer Agency and Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
Exp Hematol. 1999 Sep;27(9):1418-27. doi: 10.1016/s0301-472x(99)00078-8.
The purpose of this study was to develop a simple assay for quantitating transplantable human lymphomyeloid stem cells (competitive repopulating units [CRU]) to enable comparison among the numbers and types of progeny generated in NOD/ SCID mice by such cells from different ontologic sources. Sub-lethally irradiated NOD/SCID mice were transplanted with varying numbers of CD34+ cell-enriched suspensions of human fetal liver, cord blood, or adult marrow cells. The types and numbers of human cells present in the marrow of the mice were measured 6 to 8 weeks later using flow cytometry, in vitro progenitor assays, and secondary transplant endpoints. Frequencies of human CRU obtained by limiting dilution analysis of mice repopulated 6 to 8 weeks posttransplant were the same when the lymphoid and myeloid progeny of CRU were both detected by specific immunophenotypic endpoints as when in vitro myeloid progenitor assays were used to detect CRU myelopoietic activity. The average output per injected CRU of very primitive cells (CD34(+)CD38(-) cells, LTC-IC, and secondary CRU) was found to be highest for fetal liver CRU and progressively decreased (up to >100-fold) for ontologically older CRU. In contrast, the average output of mature cells was highest for cord blood CRU and lowest for fetal liver CRU, despite equivalent production of intermediate progenitors. Differences in the relative numbers of mature lymphoid, myeloid, and erythroid progeny produced by CRU from different ontologic sources were also seen. Finally, evidence of a transplantable human lymphoid-restricted cell present throughout ontogeny was obtained. A simpler and easier assay for enumerating transplantable human stem cells with lymphomyeloid reconstituting activity has been described, and its specificity and sensitivity validated. The use of this assay has revealed ontogeny-associated differences in a variety of functional attributes of human stem cells proliferating and differentiating in an in vivo, but xenogeneic, setting.
本研究的目的是开发一种简单的检测方法,用于定量可移植的人类淋巴髓系干细胞(竞争性重建造血单位[CRU]),以便比较不同本体来源的此类细胞在NOD/SCID小鼠中产生的子代数量和类型。对亚致死剂量照射的NOD/SCID小鼠移植不同数量的富含CD34+细胞的人胎肝、脐血或成人骨髓细胞悬液。6至8周后,使用流式细胞术、体外祖细胞检测和二次移植终点来测量小鼠骨髓中存在的人类细胞的类型和数量。当通过特定免疫表型终点检测CRU的淋巴样和髓样子代时,与使用体外髓样祖细胞检测来检测CRU的髓系造血活性时相比,通过对移植后6至8周重新填充的小鼠进行极限稀释分析获得的人类CRU频率相同。发现对于胎肝CRU,每个注射的CRU产生的非常原始细胞(CD34(+)CD38(-)细胞、长期培养起始细胞[LTC-IC]和二次CRU)的平均产量最高,而对于本体年龄较大的CRU则逐渐降低(高达>100倍)。相比之下,尽管中间祖细胞的产生量相当,但成熟细胞的平均产量对于脐血CRU最高,对于胎肝CRU最低。还观察到不同本体来源的CRU产生的成熟淋巴样、髓样和红系子代的相对数量存在差异。最后,获得了在整个个体发育过程中存在可移植的人类淋巴系限制细胞的证据。本文描述了一种更简单、更容易的检测方法,用于计数具有淋巴髓系重建活性的可移植人类干细胞,并验证了其特异性和敏感性。使用该检测方法揭示了在体内但异种环境中增殖和分化的人类干细胞的各种功能属性中与个体发育相关的差异。